Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

NCT06057402 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06057402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06057402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Recruiting
Start date
October 3, 2023
Completion date
February 22, 2032
Enrollment
80 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma